SEC Form 4 · accession 0001209191-18-039725
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Bahrt
Officer — Chief Medical Officer
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 7:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 25, 2018 | S | 7,700 | $0.8451 | D | 47,120 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- F2The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.845 to $0.8525, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3Includes 14,493 shares of the Issuer's common stock subject to RSUs that will vest on 6/22/19, the four-year anniversary of the 6/22/15 grant date, subject to continued service through such date.